Bellalgin (Bellalgin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceBelladonna Leaf Extract + Benzocaine + Metamizole Sodium + Sodium HydrocarbonateBelladonna Leaf Extract + Benzocaine + Metamizole Sodium + Sodium Hydrocarbonate
Similar drugsTo uncover
  • Bellalgin
    pills inwards 
    DALHIMFARM, OJSC     Russia
    • Dosage form: & nbsppills
    Composition:

    1 tablet contains:

    active substances: metamizol sodium (analgin) 0.25 g; benzocaine (anesthesin) 0.25 g; sodium bicarbonate 0.1 g; bellads (belladonna) thick extract - 0,015 g;

    Excipients: potato starch - 0.054816 g, calcium stearate 0.0072 g, talc 0.01008 g, polysorbate 80 (tween 80) 0.001224 g, silicon dioxide colloid (aerosil) 0.00288 g, sodium starch glycolate (sodium carboxymethyl starch) - 0.0288 g.

    Pharmacotherapeutic group:Analgesic combined (analgesic non-narcotic agent + local anesthetic + antispasmodic + antacid)
    ATX: & nbsp

    A.03.D   Spasmolytics in combination with analgesics

    Pharmacodynamics:

    Combined drug. The effect is determined by the effects of the components: spasmolytic (lowering the tone of smooth muscle organs, including the gastrointestinal tract) and antisecretory effects (decreased secretion of the gastric, pancreatic, bronchial, salivary, sweat glands and bile secretion) are caused by alkaloids of the belladonna extract,local anesthetic and analgesic effect is caused by metamizol sodium and benzocaine, antacid - sodium bicarbonate.

    Indications:As a symptomatic means for eliminating the pain syndrome in diseases of the gastrointestinal tract (GIT) accompanied by increased secretion of gastric juice and spasms of smooth muscles (hyperacid gastritis, peptic ulcer and duodenal ulcer.
    Contraindications:

    Hypersensitivity to the components of the drug, glaucoma, prostatic hyperplasia, oppression of hematopoiesis (leukopenia, agranulocytosis, cytostatic or infectious neutropenia), severe hepatic and / or renal insufficiency, hereditary hemolytic anemia associated with deficiency of glucose-6-phosphate dehydrogenase, bronchial asthma induced acetylsalicylic acid and other non-steroidal anti-inflammatory drugs, pregnancy (especially in the first trimester and in the last 6 weeks), the period of breast on breastfeeding, age to 18 years.

    Carefully:

    Diseases of the kidneys (pyelonephritis, glomerulonephritis, including in the anamnesis), long-term abuse of ethanol.

    Dosing and Administration:

    Adults inside, before meals, 1 tablet 2-3 times a day. The maximum single dose - no more than 3 tablets, daily - 10 tablets. Duration of treatment should not exceed 3 days. It is not recommended to apply systematically.

    Side effects:

    From the urinary system: renal dysfunction, oliguria, anuria, proteinuria, interstitial nephritis, urine staining in red.

    Allergic reactions: urticaria (including conjunctiva and mucous membranes of the nasopharynx), angioedema; in rare cases - malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell syndrome), bronchospastic syndrome, anaphylactic shock.

    On the part of the organs of hematopoiesis: agranulocytosis, leukopenia, thrombocytopenia.

    Other: lowering blood pressure, dry mouth, thirst, constipation, mydriasis, paresis of accommodation, temporary visual impairment, dysuria, urinary retention, palpitation, drowsiness, dizziness, psychomotor agitation, convulsions.

    Overdose:

    Symptoms: nausea, vomiting, gastralgia, oliguria, hypothermia,decrease in blood pressure, tachycardia, dyspnea, tinnitus, drowsiness, delirium, impaired consciousness, acute agranulocytosis, hemorrhagic syndrome, acute renal and / or hepatic insufficiency, convulsions, respiratory muscle paralysis.

    Treatment: gastric lavage, saline laxatives, Activated carbon; carrying out forced diuresis, hemodialysis, with the development of convulsive syndrome - intravenous diazepam and high-speed barbiturates.

    Interaction:

    Enhances the effects of ethanol; simultaneous use with chlorpromazine or other phenothiazine derivatives can lead to the development of severe hyperthermia.

    Radiopaque drugs, colloidal blood substitutes and penicillin should not be used during treatment with metamizole.

    With the simultaneous administration of cyclosporine, the concentration of the latter in the blood decreases.

    Metamizole sodium, displacing from the bond with protein oral hypoglycemic drugs, indirect anticoagulants, glucocorticosteroids and indomethacin, increases their activity.

    Phenylbutazone, barbiturates and other hepatoinductors with simultaneous administration decrease the effectiveness of metamizole.

    Simultaneous appointment with other non-narcotic analgesics, tricyclic antidepressants, contraceptive hormonal drugs and allopurinol may lead to increased toxicity.

    Sedative and anxiolytic drugs (tranquilizers) increase the analgesic effect of metamizole.

    Thiamazole and cytostatics increase the risk of developing leukopenia.

    The effect is enhanced codeine, H2-gistaminoblockers and propranolol (slows inactivation).

    Special instructions:

    In the treatment of patients receiving cytotoxic drugs, metamizole sodium should be administered only under medical supervision.

    Patients with atopic bronchial asthma and pollinosis have an increased risk of developing allergic reactions.

    Against the background of taking metamizole sodium, the development of agranulocytosis is possible, in connection with which, when an unmotivated rise in temperature, chills, sore throats, difficulty swallowing, stomatitis, as well as in the development of phenomena of vaginitis or proctitis, immediate withdrawal of the drug is necessary.With prolonged use, it is necessary to monitor the picture of peripheral blood.

    It is inadmissible to use to relieve acute pain in the abdomen (until the cause is clarified).

    Against the background of treatment, it is possible to stain urine in red due to the release of a metabolite.

    Effect on the ability to drive transp. cf. and fur:

    Avoid administration of the drug to people who drive vehicles or engage in activities that require increased visual acuity.

    Form release / dosage:Pills.
    Packaging:Packings for cells, planimetric (10).
    Storage conditions:

    In a dry place protected from light.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:P N000833 / 01
    Date of registration:27.10.2008 / 17.11.2014
    Expiration Date:Unlimited
    The owner of the registration certificate:DALHIMFARM, OJSC DALHIMFARM, OJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspDALHIMFARM, OJSCDALHIMFARM, OJSC
    Information update date: & nbsp21.01.2017
    Illustrated instructions
      Instructions
      Up